SCHEMBL45030

SCHEMBL45030

COC(=O)c1cccc2[nH]ccc12

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR4A2 P43354 8/20 0.63
CREBBP Q92793 1/20 0.63
TUBB4A P04350 2/20 0.56
TUBB P07437 2/20 0.56
TUBA3C P0DPH7 2/20 0.56
TUBA1B P68363 2/20 0.56
TUBA4A P68366 2/20 0.56
TUBB4B P68371 2/20 0.56
TUBB3 Q13509 2/20 0.56
TUBB2A Q13885 2/20 0.56
TUBB8 Q3ZCM7 2/20 0.56
TUBA3E Q6PEY2 2/20 0.56
TUBA1A Q71U36 2/20 0.56
TUBA1C Q9BQE3 2/20 0.56
TUBB6 Q9BUF5 2/20 0.56
TUBB2B Q9BVA1 2/20 0.56
TUBB1 Q9H4B7 2/20 0.56
PIM3 Q86V86 2/20 0.52
DHPS P49366 1/20 0.52
PIM1 P11309 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30430559 1.00 NR4A2 (0.63) NR4A2CREBBPTUBB4ATUBBTUBA3C
Pyrimidine SCHEMBL28425509 0.90 NR4A2 (0.52) NR4A2CREBBPTUBB4ATUBBTUBA3C
Pyridine SCHEMBL28511928 0.90 NR4A2 (0.52) NR4A2CREBBPTUBB4ATUBBTUBA3C
SCHEMBL2004209 0.86 NR4A2 (0.49) NR4A2CREBBPTUBB4ATUBBTUBA3C
SCHEMBL27658621 0.82 DHPS (0.52) NR4A2CREBBPTUBB4ATUBBTUBA3C
SCHEMBL6417970 0.82 NUDT1 (0.57) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL7496719 0.82 KDM4E (0.54) NR4A2CREBBPTUBB4ATUBBTUBA3C
SCHEMBL27788680 0.81 TUBB4A (0.51) NR4A2CREBBPTUBB4ATUBBTUBA3C
SCHEMBL827588 0.80 PBRM1 (0.59) NR4A2CREBBPTUBB4ATUBBTUBA3C
SCHEMBL29497247 0.80 PBRM1 (0.59) NR4A2CREBBPTUBB4ATUBBTUBA3C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 602 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118978469-B Preparation process of (indole-4-yl) methanol 安徽实特医药科技有限公司 2025-01-24 CN claimed
CN-118978469-A Preparation process of (indole-4-yl) methanol 安徽实特医药科技有限公司 2024-11-19 CN claimed
CN-112574093-B Novel green method for preparing 3-diaryl methyl substituted indole compound 湖南理工学院 2022-10-04 CN claimed
CN-112574093-A Novel green method for preparing 3-diaryl methyl substituted indole compound 湖南理工学院 2021-03-30 CN claimed
EP-3080097-A1 INHIBITORS OF BRUTON'S TYROSINE KINASE F. Hoffmann-La Roche AG (CH) 2016-10-19 EP claimed
WO-2015086635-A1 INHIBITORS OF BRUTON'S TYROSINE KINASE F. HOFFMANN-LA ROCHE AG (CH) 2015-06-18 WO claimed
CN-101942497-A Method for quickly screening oxygenase microbes or oxygenase genes CHENGDU INST BIOLOGY CAS 2011-01-12 CN claimed
EP-1794163-A1 METHOD OF PREPARING POLY(ADP-RIBOSE) POLYMERASES INHIBITORS Pfizer, Inc. (US) 2007-06-13 EP claimed
WO-2006033003-A1 METHOD OF PREPARING POLY(ADP-RIBOSE) POLYMERASES INHIBITORS PFIZER, INC. (US) 2006-03-30 WO claimed
US-6306203-B1 FOR USE IN INK JET PRINTING, INCLUDING PIEZOELECTRIC INK JET PRINTING AND ACOUSTIC INK JET PRINTING XEROX CORPORATION 2001-10-23 US claimed
US-12577243-B2 Monoacylglycerol lipase modulators JANSSEN PHARMACEUTICA NV (BE) 2026-03-17 US disclosed
EP-3856178-B1 MONOACYLGLYCEROL LIPASE MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2026-03-11 EP disclosed
US-12570675-B2 Boronic acid compounds LG CHEM, LTD. (KR) 2026-03-10 US disclosed
US-12559455-B2 Compound as a UBR box domain ligand AUTOTAC INC. (KR) 2026-02-24 US disclosed
US-20250388593-A1 CEREBLON E3 LIGASE BINDING COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND PRODUCTION METHOD THEREFOR MITSUBISHI TANABE PHARMA CORPORATION (JP) 2025-12-25 US disclosed
US-4435403-A TRANQUILIZERS SCHERING AKTIENGESELLSCHAFT (DE) 1984-03-06 US disclosed
US-4394514-A Processes for preparing 4-substituted indoles SMITHKLINE BECKMAN CORPORATION (US) 1983-07-19 US disclosed
EP-0054507-A2 3-Substituted beta-carbolines, process for their production and compositions containing them SCHERING AKTIENGESELLSCHAFT (DE) 1982-06-23 EP disclosed
US-3978066-A Certain 4,6-dihydropyrrolotriazoline-quinoline derivatives AYERST, MCKENNA AND HARRISON LTD. (CA) 1976-08-31 US disclosed
US-3950343-A PYRROLOISOQUINOLINE DERIVATIVES AYERST, MCKENNA AND HARRISON LTD. (CA) 1976-04-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12570675-B2 Boronic acid compounds PSMB6, PSMB3, PSMB2 NR4A2 1564/4885CREBBP 3885/4885TUBB4A 3187/4885
US-12577243-B2 Monoacylglycerol lipase modulators MGLL, LPL, FAAH NR4A2 1245/4885CREBBP 2825/4885TUBB4A 3091/4885
US-12559455-B2 Compound as a UBR box domain ligand UBR4, UBTF, UBQLN1 NR4A2 80/4885CREBBP 453/4885TUBB4A 952/4885
US-20250388593-A1 CEREBLON E3 LIGASE BINDING COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND PRODUCTION METHOD THEREFOR CRBN, CUL1, CBL NR4A2 1071/4885CREBBP 722/4885TUBB4A 1933/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.